Quest Pharmatech Current Assets

What does Quest Pharmatech do? Quest PharmaTech, Inc. operates as a biotechnology company headquartered in Edmonton, Alberta, focusing on the development and commercialization of antibody-based immunotherapeutic products for cancer. The firm aims to improve the quality of life through its proprietary MAb-AR9.6, which targets MUC16 as a diagnostic agent. This asset is licensed from the University of Nebraska Medical Centre and is currently in the late preclinical stage of development. The company generates value through strategic equity positions in specialized biotechnology entities. Quest PharmaTech holds a 42.5% ownership interest in OncoQuest Inc., a firm developing combinatorial immunotherapy products for cancer treatment. OncoQuest utilizes a technology platform featuring a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G and E class, targeting CA125, MUC1, PSA, Her2/neu, CA 19.9, and TAG72 to enhance tumor specific immunity. Additionally, the firm maintains a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer within the Greater China territory. These investments allow Quest PharmaTech to extend its reach into specific geographic and therapeutic segments while leveraging the proprietary technologies and platforms of its partner companies. Quest Pharmatech is one of the most popular companies on Eulerpool.